嘉事堂药业股份有限公司 嘉事堂药业股份有限公司 独立董事关于第七届董事会第六次会议 相关事项的独立意见 作为嘉事堂药业股份有限公司（以下简称"公司"）独立董事，我们根据《深 圳证券交易所上市公司规范运作指引》、《关于在上市公司建立独立董事制度的指 导意见》、《中小企业板上市公司内部审计工作指引》等相关法律法规和公司的相 关规定，承诺独立履行职责，未受公司主要股东、实际控制人或者与公司及其主 要股东、实际控制人存在利害关系的单位或个人的影响，认真审阅了公司第七届 董事会第六次会议有关文件，本着勤勉尽责的态度，基于独立、审慎、客观的立 场，发表如下独立意见： （此页无正文，为嘉事堂药业股份有限公司独立董事对公司第七届董事会 第六次会议相关事项的独立意见之签字页） 嘉事堂药业股份有限公司全体独立董事（签字）： 一、对公司 2023 年第三季度报告的独立意见 我们作为公司独立董事认为：公司 2023 年第三季度报告真实、全面地反映 了公司的财务状况；公司 2023 年第三季度财务报告的编报符合上市公司相关的 会计准则，董事会履行了诚信义务；经认真审核，我们未发现 2023 年第三季度 报告中存在遗漏、虚报等误导公司或 ...

嘉事堂药业股份有限公司 关于召开 2023 年第一次临时股东大会的通知公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、会议召开的基本情况 1、 股东大会届次：本次股东大会是嘉事堂药业股份有限公司 2023 年第一 次临时股东大会。 股票代码：002462 股票简称：嘉事堂 公告编号：2023-22 2、 股东大会召集人：公司董事会。 根据嘉事堂药业股份有限公司（以下简称"公司"）《章程》的相关规定，公 司第七届董事会第六会议于 2023 年 10 月 30 日召开，会议决议拟定于 2023 年 11 月 17 日（星期五）召开公司 2023 年第一次临时股东大会。 3、会议召开的合法、合规性说明：董事会召集本次股东大会符合《公司法》、 《上市公司股东大会规则》等有关法律、行政法规、部门规章、规范性文件、和 本公司章程的规定。 4、 会议召开时间： （1） 现场会议召开时间：2023 年 11 月 17 日（星期五）15:00 （2） 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2023 年 11 月 17 日 9:15—9:2 ...

证券代码：002462 证券简称：嘉事堂 公告编号：2023-20 嘉事堂药业股份有限公司 第七届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 1、关于 2023 年第三季度报告的议案 同意 8 票，反对 0 票，弃权 0 票，议案获得通过。 经审议，监事会认为公司《2023 年第三季度报告》报告的内容真实、准确、 完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大 遗漏，报告编制和审核的程序符合法律、行政法规和中国证监会的规定。 《2023 年第三季度报告》（公告编号：2023-18）详见 2023 年 10 月 31 日《证 券日报》、《证券时报》与巨潮资讯网（http://www.cninfo.com.cn）的公告。 2、关于续聘会计师事务所的议案 同意 8 票，反对 0 票，弃权 0 票，议案获得通过。 经审议，监事会认为续聘安永华明会计师事务所（特殊普通合伙）符合法律、 行政法规和中国证监会的规定。 一、监事会会议召开情况 嘉事堂药业股份有限公司（以下简称"公司"、"本公司"）第七届监事会第 五次会议于 ...

证券代码：002462 证券简称：嘉事堂 公告编号：2023-19 嘉事堂药业股份有限公司 第七届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 嘉事堂药业股份有限公司（以下简称"公司"、"本公司"）第七届董事会第 六次会议于 2023 年 10 月 17 日以信息、电子邮件的方式发出会议通知。会议于 2023 年 10 月 30 日 14 时以现场结合通讯表决的方式召开。会议应表决的董事 9 名，实际表决的董事 9 名（其中赵保富、潘蔚、蔡卫东、梁雨、熊焰、张海燕 6 位董事以通讯表决方式出席会议）。会议由董事长主持。本次会议的召开及表决 程序符合《公司法》、《公司章程》及《董事会议事规则》的有关规定。 二、董事会会议审议情况 1、关于 2023 年第三季度报告的议案 同意 9 票，反对 0 票，弃权 0 票，议案获得通过。 经审议，董事会认为公司《2023 年第三季度报告》报告的内容真实、准确、 完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大 遗漏，报告编制和审核的程序符合法律、行政 ...

1.基本信息，安永华明会计师事务所（特殊普通合伙）以下简称"安永华明"， 于 1992 年 9 月成立，2012 年 8 月完成本土化转制，从一家中外合作的有限责任 制事务所转制为特殊普通合伙制事务所。安永华明总部设在北京，注册地址为北 京市东城区东长安街 1 号东方广场安永大楼 17 层 01-12 室。 证券代码：002462 证券简称：嘉事堂 公告编号：2023-21 嘉事堂药业股份有限公司 拟续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、拟续聘会计师事务所的基本情况 2.人员信息，截至 2022 年末拥有合伙人 229 人，首席合伙人为毛鞍宁先生。 安永华明一直以来注重人才培养，截至 2022 年末拥有执业注册会计师 1818 人， 其中拥有证券相关业务服务经验的执业注册会计师超过 1500 人, 注册会计师中 签署过证券服务业务审计报告的注册会计师超过 400 人。 3.业务规模，安永华明 2022 年度业务总收入人民币 59.06 亿元，其中，审 计业务收入人民币 56.69 亿元，证券业务收入人民币 24.97 亿元 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥14,877,717,780.55, representing a 17.09% increase compared to ¥12,706,434,721.05 in the same period last year[21]. - Net profit attributable to shareholders decreased by 8.26% to ¥155,489,204.07 from ¥169,486,663.20 year-on-year[21]. - The net profit after deducting non-recurring gains and losses was ¥149,081,767.85, down 7.87% from ¥161,822,553.18 in the previous year[21]. - Basic earnings per share decreased by 8.62% to ¥0.53 from ¥0.58 in the same period last year[21]. - The company reported a total sales revenue of 1,071.70 million for its subsidiary, with a year-on-year increase of 79.48%[58]. - The subsidiary sales for another segment reached 960.67 million, reflecting a growth of 82.60% compared to the previous period[58]. - The net profit for the first half of 2023 was CNY 231.60 million, a decrease of 9.5% from CNY 255.97 million in the same period last year[126]. - The company's total liabilities decreased to CNY 2.49 billion from CNY 2.99 billion year-on-year, reflecting a reduction of 16.5%[125]. - Total equity increased to CNY 3.40 billion, up from CNY 3.35 billion, representing a growth of 1.5%[125]. - The company reported a net profit margin of 6.8% for the first half of 2023, down from 7.2% in the previous year[137]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, reaching ¥851,290,876.21, a 173.54% increase from a negative cash flow of ¥1,157,613,569.68 in the same period last year[21]. - The company's cash and cash equivalents increased to ¥430,962,257.68, a 152.77% rise from a negative balance of ¥816,666,963.70 in the previous year[38]. - Cash and cash equivalents at the end of the period increased to CNY 2,130,237,424.86 from CNY 1,384,325,191.82 at the end of the previous year, marking an increase of approximately 54%[132]. - The cash inflow from financing activities totaled CNY 2,945,241,105.05, compared to CNY 2,319,745,425.01 in the same period last year, indicating an increase of approximately 27%[132]. - The company's cash and cash equivalents at the end of the period stood at ¥659,005,459.57, up from ¥217,860,235.65 at the end of the previous year[134]. Assets and Liabilities - Total assets at the end of the reporting period were ¥16,929,216,099.46, up 2.25% from ¥16,556,608,348.72 at the end of the previous year[21]. - The net assets attributable to shareholders increased by 1.60% to ¥4,143,082,996.40 from ¥4,078,022,999.53 at the end of the last year[21]. - Current liabilities totaled CNY 10,662,226,637.98, an increase from CNY 10,415,005,654.32, reflecting a rise of 2.37%[118]. - Total liabilities amounted to CNY 10,887,624,757.08, an increase from CNY 10,635,004,233.56, reflecting a growth of 2.37%[118]. - The total assets of the company at the end of the reporting period were CNY 8,000 million, showing an increase of 5.6% from the previous year[141]. Business Operations and Strategy - The pharmaceutical wholesale segment accounted for 94.20% of total revenue, with sales amounting to ¥14,014,276,387.67, up 19.96% year-on-year[39]. - The company remains focused on its core business and aims to contribute to the health strategy of the country[28]. - The company has established partnerships with over 2,000 upstream manufacturers, enhancing product variety and quality[33]. - The company is focusing on innovation and transformation, including the establishment of regional innovation centers and enhancing digital integration in healthcare[31]. - The company plans to enhance its digital capabilities by promoting smart healthcare and online pharmaceutical distribution, aiming to transform offline customers to online[71]. - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[121]. - The company plans to focus on market expansion and new product development in the upcoming quarters[126]. - The company aims to achieve a revenue growth target of 10% for the full year 2023[142]. Research and Development - Research and development expenses for the first half of 2023 accounted for 5.1% of total revenue, indicating a focus on innovation[137]. - Research and development expenses for the first half of 2023 amounted to CNY 227 million, accounting for 6.8% of total revenue[144]. - The company has initiated research and development for new technologies aimed at enhancing its product offerings[149]. Social Responsibility - The company donated over 150,000 yuan worth of medicines to support rural areas during the Spring Festival, demonstrating its commitment to social responsibility[72]. Corporate Governance - The half-year financial report has not been audited, indicating that the financial results are still subject to review[78]. - The financial statements were approved by the board of directors on August 30, 2023[152]. - The company did not undergo any changes in its controlling shareholder or actual controller during the reporting period[106]. - There were no changes in the shareholding of directors, supervisors, and senior management during the reporting period[105]. Market Risks - The company is facing risks due to the implementation of volume-based procurement policies, which have significantly impacted the medical device industry[59]. - To mitigate the impact of price reductions in pharmaceuticals and medical supplies, the company is actively adjusting its product structure and expanding new product introductions[61]. - The company has extended the payment terms for accounts receivable, which has increased financing costs and put pressure on operating profits[60].

1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 嘉事堂药业股份有限公司 2023 年第一季度报告 证券代码：002462 证券简称：嘉事堂 公告编号：2023-11 嘉事堂药业股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： □是 否 1 嘉事堂药业股份有限公司 2023 年第一季度报告 一、主要财务数据 (一) 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 口是 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | | | | (%) | | | 营业收入(元) | 6.756.081.779.54 | 6. 460. 665. 483. 96 | | 4.57% | ...

Financial Performance - The company's operating revenue for 2022 was CNY 26,219,790,244.85, representing a 2.32% increase compared to CNY 25,625,618,769.65 in 2021[18] - The net profit attributable to shareholders for 2022 was CNY 296,935,789.27, a decrease of 16.09% from CNY 353,876,773.64 in the previous year[18] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 284,354,722.16, down 17.91% from CNY 346,379,731.51 in 2021[18] - The basic earnings per share for 2022 was CNY 1.02, a decline of 15.70% compared to CNY 1.21 in 2021[18] - The total assets at the end of 2022 amounted to CNY 16,556,608,348.72, reflecting a 10.84% increase from CNY 14,937,549,976.72 at the end of 2021[18] - The net assets attributable to shareholders at the end of 2022 were CNY 4,078,022,999.53, which is a 4.93% increase from CNY 3,886,549,170.39 in 2021[18] - The company reported a net cash flow from operating activities of CNY -163,448,296.26, a significant decrease of 117.90% compared to CNY 913,127,423.08 in the previous year[18] - The weighted average return on equity for 2022 was 7.49%, down from 9.42% in 2021[18] - The company reported a net profit of ¥46,831,250 in 2022, while the net cash flow from operating activities was -¥16,344,830, indicating a significant discrepancy of ¥63,176,080[63] - The company reported a total revenue of 440.1 million in 2022, a decrease of 20.5% compared to 2021[102] - The net profit for 2022 was 86.53 million, down from 259.6 million in 2021, representing a decline of 66.7%[102] Revenue Breakdown - The pharmaceutical wholesale segment generated CNY 24.16 billion, accounting for 92.14% of total revenue, but saw a decline of 1.48% compared to the previous year[44] - The company’s logistics revenue was CNY 284 million, which is a decrease of 21.92% year-on-year[46] - The retail pharmacy segment reported revenue of CNY 1.78 billion, marking a significant increase of 39.92% compared to 2021[46] - The company’s Beijing region revenue increased by 9.66% to CNY 10.55 billion, while other regions saw a decline of 9.66%[44] Strategic Initiatives - The company is actively expanding its e-commerce business, resulting in noticeable revenue growth in the retail segment[35] - The company is focusing on optimizing product structure and expanding new product lines in response to industry policy changes, indicating strategic adaptability[33] - The company aims to maintain and enhance its market share in pharmaceuticals and medical devices, focusing on high-quality development in 2023[80] - The company plans to optimize and expand its new health-related business segments, including rehabilitation products and health foods, to counteract pricing pressures[80] - The company is considering strategic acquisitions to enhance its product portfolio and market presence, with a budget of up to 300 million RMB for potential targets[123] Governance and Compliance - The company emphasizes the importance of risk management and compliance, integrating risk management into all operational aspects[81] - The company has a structured governance framework that complies with relevant laws and regulations, ensuring the protection of shareholder rights[85] - The company has established a performance evaluation and incentive mechanism to enhance operational efficiency[91] - The company maintains a complete and independent financial accounting system, complying with accounting standards and ensuring independent financial decision-making[97] - The company has implemented a robust internal control system to support its financial management and decision-making processes[97] Leadership Changes - There were significant changes in the board, with multiple directors resigning due to term completion, including Sun Jianxin and Xu Shuai[103][104] - The company has undergone significant changes in its board and supervisory roles, with multiple appointments and departures effective December 14, 2022[111] - Huang Yibin has been elected as the President and Director of the company since December 14, 2022[112] - The company is focusing on expanding its management team with professionals from diverse backgrounds, enhancing its operational capabilities[112][113][114][115] Employee and Remuneration - The total remuneration for directors, supervisors, and senior management in 2022 amounted to CNY 158.70 million[132] - The chairman, Xu Wenli, received a total pre-tax remuneration of CNY 39.88 million in 2022[134] - The total pre-tax remuneration for the president, Huang Yibin, was CNY 18.04 million[134] - The company’s remuneration management system was approved by the board of directors and is based on performance evaluations[131] Social Responsibility and Community Engagement - 嘉事堂药业在2022年为乡村卫生室免除运费送药数千笔，服务近2000家乡村卫生室[165] - 公司在2022年定点帮扶资金划转至集团定点帮扶专户为湖南定点帮扶县提供50万元支持[166] - 嘉事堂药业在2022年积极落实乡村振兴工作，承担国企社会责任[161] Environmental Compliance - 嘉事堂药业在2022年未因环境问题受到行政处罚，保持良好的环境合规记录[159] - 公司倡导绿色办公，鼓励节水节电和资源回收，推动可持续发展[159]

嘉事堂药业股份有限公司 关于举办 2022 年年度报告网上业绩说明会的通知公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 嘉事堂药业股份有限公司（以下简称"嘉事堂"或"公司"）第七届董事 会第二次会议通过了《2022 年年度报告全文及其摘要》,并登载于 2023 年 4 月 21 日的《中国证券报》、《证券时报》和巨潮资讯网(www.cninfo.com.cn）。 欢迎广大投资者积极参与本次网上说明会。 股票代码：002462 股票简称：嘉事堂 公告编号：2023-09 （问题征集专题页面二维码） 公司定于 2023 年 4 月 27 日（星期四）15:00-17:00 在全景网举办 2022 年 度业绩说明会，本次年度业绩说明会将采用网络远程的方式举行，投资者可登 陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次年度业绩说 明会。 出席本次说明会的人员有：公司董事长续文利先生、总裁黄奕斌先生、副 总裁林军先生、副总裁王文鼎先生（代行董秘职责）、独立董事梁雨先生。 为充分尊重投资者、提升交流的针对性，现就公司 2021 年度业 ...

Financial Performance - Revenue for Q3 2022 reached ¥7,574,345,325.09, an increase of 11.57% year-over-year[5] - Net profit attributable to shareholders was ¥77,635,692.64, a decrease of 14.17% compared to the same period last year[5] - Basic earnings per share for the quarter was ¥0.27, reflecting a slight increase of 0.30% year-over-year[5] - Total operating revenue for the period reached ¥20,280,780,046.14, an increase of 4.8% compared to ¥19,350,905,221.84 in the previous period[15] - Net profit for the period was ¥399,270,710.90, a decrease of 14.5% from ¥466,993,621.42 in the same period last year[17] - Earnings per share (EPS) for the period was ¥0.85, down from ¥0.91 in the previous period[18] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥15,750,748,213.30, representing a growth of 5.44% from the end of the previous year[5] - Total assets as of September 30, 2022, amounted to CNY 15,750,748,213.30, an increase from CNY 14,937,549,976.72 at the beginning of the year[12] - Current assets totaled CNY 14,170,834,228.51, up from CNY 13,285,290,480.49 at the beginning of the year[12] - Total liabilities as of September 30, 2022, were CNY 9,893,924,842.00, compared to CNY 9,280,992,337.21 at the beginning of the year[13] - The total assets and liabilities amounted to ¥15,750,748,213.30, compared to ¥14,937,549,976.72 in the previous period[14] Cash Flow - Cash flow from operating activities showed a net outflow of ¥727,857,246.57, a significant decrease of 507.21% compared to the previous year[5] - Cash flow from operating activities showed a net outflow of ¥727,857,246.57, compared to a net inflow of ¥178,741,693.17 in the prior period[19] - The net cash flow from investment activities was -23,465,884.68, compared to -38,320,605.14 in the previous year, indicating an improvement[20] - Cash inflow from financing activities totaled 3,797,361,570.29, up from 3,094,074,447.25 year-over-year[20] - The net cash flow from financing activities was 137,790,671.64, a significant recovery from -440,398,843.78 in the same quarter last year[20] - The total cash and cash equivalents at the end of the period were 1,587,459,695.91, slightly up from 1,578,790,810.05 year-over-year[20] - Cash inflow from borrowing was 3,701,428,927.91, compared to 2,808,000,000.00 in the previous year, reflecting increased leverage[20] - The company had cash outflows for debt repayment amounting to 3,418,388,925.89, compared to 3,054,571,061.81 in the previous year[20] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period was 22,806[10] - The total equity attributable to shareholders of the parent company increased to ¥4,030,742,909.75 from ¥3,886,549,170.39[14] Operational Highlights - Trade receivables decreased by 54%, primarily due to the maturity and payment of received bills[9] - The company reported a 41% increase in asset disposal gains, attributed to higher asset disposal revenues[9] - Government subsidies received increased by 79.8%, contributing to the rise in non-operating income[9] - The company plans to expand its new business operations, as indicated by a 35% increase in prepayments[9] - The company reported a significant increase in research and development expenses, totaling ¥2,715,829.05 for the period[15] - The company experienced a credit impairment loss of ¥50,846,208.46, compared to ¥13,569,941.97 in the previous period[17] - The company aims to enhance market expansion and product development strategies in the upcoming quarters[18] Financing Activities - Cash received from borrowings increased by 31.8%, primarily due to an increase in borrowings during the period[10] - Other financing cash received decreased by 77.2%, as the required funds were fully obtained from banks, reducing the need for alternative financing[10] - Other financing cash paid decreased by 83.5%, mainly due to a reduction in cash that needed to be repaid[10] Audit Information - The company did not conduct an audit for the third quarter report[21]